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The glycolytic enzyme glucokinase (GCK) is a glucose sensor that plays a key role in maintaining blood glucose homeostasis. In the pancreatic β-cells, GCK controls insulin secretion and biosynthesis ([@r1]). In the liver, GCK regulates glycogen synthesis and gluconeogenesis, and its activity is competitively inhibited by glucokinase regulatory protein (GCKR) ([@r1],[@r2]).

In support of these functions, rare mutations in the *GCK* gene have been found to be associated with maturity-onset diabetes of the young (MODY), permanent neonatal diabetes, and hyperinsulinemia of infancy ([@r3]). Moreover, a common promoter variant (−30A) (rs1799884) of *GCK* has been found to be associated with increased fasting plasma glucose (FPG) and lowered birth weight in general Caucasian populations ([@r4],[@r5]). Recently, a genome-wide association (GWA) study conducted by the Diabetes Genetics Initiative identified a common intronic polymorphism at *GCKR* (rs780094) associated with plasma triglyceride level ([@r6]). Subsequent independent studies in Danish ([@r7]) and French ([@r8]) populations, as well as meta-analysis and fine- mapping ([@r9]) studies, confirmed that the minor alleles of rs780094 and rs1260326 (Pro446Leu), which are in strong linkage disequilibrium (LD), were associated with higher levels of triglyceride and C-reactive protein but lower fasting glucose, insulin, and/or insulin resistance.

In this study, we examined the association of the *GCKR* rs780094 and *GCK* rs1799884 polymorphisms with type 2 diabetes--related quantitative traits in two independent samples of 600 adult and 986 adolescent Chinese residents in Hong Kong. Due to the intimate relationship between glucose and lipid metabolisms ([@r10]) and the functional interaction between GCKR and GCK, we also hypothesized the presence of epistasis effects between these two single nucleotide polymorphisms (SNPs) on FPG and fasting triglyceride levels.

We genotyped two SNPs, rs1799884 in *GCK* and rs780094 in *GCKR*, in a total of 1,586 healthy subjects including adults and adolescents. The frequencies of the A-allele of rs1799884 were similar between our adult (0.16) and adolescent (0.19) cohorts, as well as the HapMap CHB data (0.20). Although the T-allele frequencies of rs780094 in our data (0.46 for both cohorts) were lower than in the HapMap CHB (0.60), they were similar to the frequency reported in a group of Singapore Chinese (0.46) from a meta-analysis study ([@r9]).

The clinical characteristics of the adult and adolescent cohorts are summarized in [Table 1](#t1){ref-type="table"}. When comparing the distributions of metabolic traits among different genotype carriers of *GCKR* rs780094, we observed consistent and strong association of the minor T-allele with increased triglycerides in both adult and adolescent cohorts (4.0 × 10^−6^ \< *P* \< 0.005), after adjusting for age, sex, and BMI ([Table 2](#t2){ref-type="table"}). We also observed a strong association of the minor A-allele of *GCK* rs1799884 with increased FPG in both cohorts (*P* \< 6.4 × 10^−5^) after adjusting for covariates ([Table 3](#t3){ref-type="table"}). The associations became more significant in the combined cohort (*P* = 5.4 × 10^−7^ for triglycerides with rs780094; *P* = 3.1 × 10^−7^ for FPG with rs1799884) ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}) and remained significant after controlling for false discovery rate (*P* \< 0.0056 for triglycerides with rs780094; *P* \< 0.0028 for FPG with rs1799884). These findings are in agreement with reports from Caucasian populations ([@r4],[@r6]--[@r9],[@r11]--[@r13]), as well as a recent Japanese study (mean triglyceride levels of 1.07, 1.13, and 1.18 mmol/l, respectively, for CC, CT, and TT genotypes of rs780094, *P* = 0.097) ([@r14]).

We further examined possible gene-gene interaction effects of *GCKR* rs780094 and *GCK* rs1799884 on fasting triglycerides and FPG in the combined cohort using additive genetic models ([Fig. 1*A*](#f1){ref-type="fig"}). There was a highly significant interaction effect between the two SNPs on FPG (*P* = 0.0025 for the interaction after adjusting for age, sex, BMI, and study cohort). Each copy of the rs1799884 A-allele was associated with a 0.18 (*P* \< 0.0001), 0.09 (*P* = 0.0002), and 0.02 mmol/l (*P* = 0.53) change in FPG levels for rs780094 TT, CT, and CC carriers, respectively. On the other hand, the T-allele of rs780094 showed a trend of increased FPG in rs1799884 AA carriers (0.14 mmol/l per allele, *P* = 0.13) but decreased FPG (−0.05 mmol/l per allele) in GG carriers (*P* = 0.0045). However, no interaction was observed for fasting triglycerides ([Fig. 1*B*](#f1){ref-type="fig"}).

Several studies have reported the reciprocal effect of the C-allele of rs7800094 with decreased triglycerides but increased FPG, as well as the joint additive effects of rs7800094 and rs1799884 on FPG levels ([@r7]--[@r9]). However, only a Danish study examined nonadditive epistasis effects, and no interaction between these two SNPs was found ([@r8]). Our results suggest a more complex scenario. The risk effect of the A-allele of GCK rs1799884 on FPG was strongest in TT carriers of rs780094, followed by CT and CC carriers. Similar to other studies, we observed that the C-allele of rs780094 was associated with increased FPG, but only in carriers of the more common GG variant of rs1799884 (*P* = 0.0045), whereas a nominal association in the opposite direction was observed for AA carriers (*P* = 0.13). This interaction explains the lack of overall association of rs7800094 with FPG and fasting insulin levels in our population.

The interaction effect is possibly due to the perturbation of the upstream GCKR/GCK system, in which failure of the receptor (GCKR) may influence the ability of GCK polymorphisms to confer effect on FPG levels. Despite smaller sample sizes in separate cohorts, these interaction effects showed a nominal significance in both adult (*P* = 0.058) and adolescent (*P* = 0.022) cohorts, suggesting that our finding is unlikely to be due to chance alone (supplementary Fig. 1*A* and *B*, available in an online appendix at <http://diabetes.diabetesjournals.org/cgi/content/full/db08-1277/DC1>). Due to the rarity of the rs1799884 AA genotype in both Europeans and Asians (4 and 3%, respectively), as well as the lower TT genotype frequency of rs7800094 in Europeans versus Asians (14 vs. 23%, respectively) ([@r7]), the lack of interaction seen in Europeans may be partly due to the rarity of the AA/TT high-risk carriers and the corresponding low power of detection. Alternatively, different risk-conferring alleles for the same gene are now increasingly recognized, which may confound the association ([@r15],[@r16]). Additional interaction analyses in other studies are warranted to clarify our findings.

Meta-analysis of the association between *GCKR* (rs780094) and fasting triglycerides in combined European and Asian cohorts showed increases of 0.10 (95% CI 0.07--0.13) and 0.22 (0.18--0.26) in standardized mean difference (SMD) for the CT and TT genotypes, respectively, when compared with the CC reference genotype (supplementary Fig. 2). Likewise, an additive trend of increases of 0.14 (0.10--0.18) and 0.31 (0.12--0.49) in SMD of FPG for AG and AA genotypes, respectively, when compared with the GG reference genotype, was observed for *GCK* (rs1799884) (supplementary Fig. 3). Due to significant heterogeneity among the study cohorts (*P* \< 0.1), the combined SMDs were calculated based on a random-effects model.

Our meta-analyses of the association between *GCKR* and triglycerides and between *GCK* and FPG, using combined European and Asian data, strongly support the additive effects of the risk alleles of the two SNPs on triglycerides and FPG. Nevertheless, there are notable differences in the effect size between the European and Asian studies. Given interethnic differences in risk-allele frequency, genetic effect size, and environmental exposure, one might expect considerable variation in the population-attributable risk of these genotypes on diabetes in different populations.

In conclusion, we have confirmed the risk associations of two common genetic polymorphisms of *GCK* and *GCKR* on type 2 diabetes--related metabolic traits as well as the significant interactive effects of these polymorphisms on FPG in healthy Chinese adults and adolescents. These risk alleles may add to the overall risk of type 2 diabetes in subjects who harbor other genetic or environmental/lifestyle factors. Finally, the interactions of these two genetic polymorphisms have provided a hypothesis to improve our understanding of dysregulation of intermediary metabolism. This hypothesis, that polymorphisms at *GCKR* may perturb the GCKR/GCK system and thus modify the effect of *GCK* polymorphisms and lead to altered glucose metabolism, warrants further functional studies.

RESEARCH DESIGN AND METHODS
===========================

The study design, ascertainment, inclusion criteria, and phenotyping of the study subjects have been described previously ([@r15],[@r17],[@r18]). All subjects were of southern Han Chinese ancestry and residing in Hong Kong. The adult cohort (mean age 41.4 ± 10.5 years, 45% male) consists of 600 participants of a community-based health screening program or hospital staff. The adolescent cohort consists of 986 healthy subjects (mean age 15.3 ± 1.9 years, 47% male) recruited from a population-based school survey for risk factor assessment. Subjects with FPG ≥6.1 mmol/l were excluded. This study was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. Written informed consent was obtained from all participants or parents of adolescents as appropriate.

All study subjects were examined in the morning after an overnight fast. Anthropometric parameters including body weight, height, and blood pressure were measured. Fasting blood samples were collected for measurement of FPG, insulin, and lipids. FPG, total cholesterol, triglycerides, and HDL cholesterol were measured enzymatically by the Roche Modular Analytics system (Roche Diagnostics, Mannheim, Germany) with precision of the assays within that specified by the manufacturer. Plasma insulin was measured by an enzyme-linked immunosorbent assay (DAKOCytomation, Cambridgeshire, U.K.).

Genotyping.
-----------

Based on the existing evidence of association of *GCKR* rs780094 and *GCK* rs1799884 polymorphisms with triglycerides, FPG, and type 2 diabetes ([@r4],[@r5],[@r7]--[@r9],[@r11],[@r12],[@r14]), these two SNPs were genotyped in all study subjects using genomic DNA. We did not attempt to test for association of all tagging SNPs of the respective genes. The *GCKR* rs1260326 polymorphism was also genotyped in the 600-adult cohort in order to assess its LD with rs780094. Due to their strong LD (*r*^2^ = 0.9 in both HapMap CEU data and the present Chinese study), subsequent analyses were performed for rs780094 only. Genotyping was performed at the McGill University and Genome Quebec Innovation Centre using primer extension of multiplex products with detection by MALDI-TOF mass spectroscopy on a Sequenom MassARRAY platform (Sequenom, San Diego, CA). Both SNPs were in Hardy-Weinberg equilibrium (*P* \> 0.05) in adult and adolescent cohorts separately, as assessed by the exact test of PLINK ([@r19]). The genotype call rates were \>92% for both SNPs. Genotyping accuracy was demonstrated by a 100% concordance rate in 26 blinded duplicate samples.

Statistical analysis.
---------------------

Continuous data are presented as mean ± SD or median (interquartile range). Plasma triglycerides and fasting plasma insulin were logarithmically transformed due to skewed distributions. Each trait was Winsorized separately in adult and adolescent cohorts by replacing extreme values with four SDs from the mean ([@r20],[@r21]). Less than 0.3% of data were replaced.

Within each cohort, associations between genotypes and metabolic traits were tested by multiple linear regression, with age, sex, and BMI as covariates (where appropriate). In the combined analysis, an additional dummy variable "study cohort" coded as 0 for adults and 1 for adolescents was included in the regression model. To assess gene-gene interaction effect on FPG and triglyceride levels, linear regression including the main and interaction effects of *GCKR* rs780094 and *GCK* rs1799884 under additive models was applied. Multiple testing of phenotypic traits and SNPs was corrected by controlling the false discovery rate using the Benjamini-Hochberg approach ([@r22],[@r23]).

Meta-analyses of the associations of *GCKR* rs780094 with triglycerides and *GCK* rs1799884 with FPG were assessed by MedCalc for Windows, version 9.2.0.0 (MedCalc Software, Mariakerke, Belgium). For the association of *GCKR* rs780094 on triglyceride, the T-allele of rs1260326 in the French study ([@r8]) was used as proxy for the T-allele of rs780094 (*r*^2^ = 0.9 in the HapMap CEU data). Hedges *G* statistic was used to calculate the SMD (the difference between the two means divided by the pooled standard deviation) across studies under the fixed effects model. To address heterogeneity of SMDs across studies (Cochran\'s *Q* statistic, *P* \< 0.1), the overall effect size (SMD) under the random-effects model, in which both random variations within and between different studies were incorporated ([@r24]), was reported.

We estimated study power using a genetic power calculator ([@r25]). Assuming an additive model with the observed frequencies of 0.46 for the T-allele of *GCKR* rs780094 and 0.17 for the A-allele of *GCK* rs1799884 in our Chinese population, our sample size has 87% power to detect a per-allele effect of increasing triglycerides by \>0.16 mmol/l for rs780094 ([@r7]) and 70% power of increasing FPG by \>0.1 mmol/l for rs1799884 ([@r12]), at an α level of 0.05. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC) unless specified otherwise. Two-tailed *P* values \<0.05 were considered statistically significant.
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###### 

Clinical and metabolic characteristics of 1,586 healthy Chinese adults and adolescents

                                    Adults              Adolescents
  --------------------------------- ------------------- -------------------
  *n* (male/female)                 600 (270/330)       986 (463/523)
  Age (years)                       41.4 ± 10.5         15.3 ± 1.9
  BMI (kg/m^2^)                     22.9 ± 3.3          19.9 ± 3.5
  Systolic blood pressure (mmHg)    115.4 ± 16.3        118.0 ± 12.5
  Diastolic blood pressure (mmHg)   72.3 ± 11.2         72.6 ± 9.6
  Total cholesterol (mmol/l)        5.0 ± 0.9           4.2 ± 0.7
  Triglycerides (mmol/l)            0.9 (0.6--1.3)      0.8 (0.6--1.0)
  HDL cholesterol (mmol/l)          1.6 ± 0.4           1.6 ± 0.3
  LDL cholesterol (mmol/l)          3.0 ± 0.8           2.3 ± 0.6
  FPG (mmol/l)                      4.8 ± 0.4           4.7 ± 0.3
  Fasting plasma insulin (pmol/l)   41.2 (26.5--58.7)   45.1 (35.3--60.4)

Data are means ± SD or median (interquartile range).

###### 

Clinical and metabolic characteristics of Chinese adults and adolescents stratified according to genotypes of GCKR rs780094

                                    Hong Kong adults    Hong Kong adolescents   Combined *P*                                                                                           
  --------------------------------- ------------------- ----------------------- ------------------- ------- ------------------- ------------------- ------------------- -------------- --------------
  *n*                               177                 284                     130                         280                 453                 200                                
  BMI (kg/m^2^)                     23.0 ± 3.2          22.9 ± 3.2              22.7 ± 3.3          0.396   19.9 ± 3.5          19.9 ± 3.5          20.0 ± 3.8          0.843          0.778
  Systolic blood pressure (mmHg)    114.8 ± 16.9        115.6 ± 16.2            115.7 ± 16.2        0.468   118.8 ± 13.5        117.9 ± 12.0        117.2 ± 12.6        0.083          0.465
  Diastolic blood pressure (mmHg)   72.1 ± 10.8         72.8 ± 11.6             71.5 ± 11.1         0.975   73.1 ± 9.8          72.2 ± 9.4          72.8 ± 9.9          0.592          0.665
  Total cholesterol (mmol/l)        5.0 ± 0.9           5.0 ± 1.0               5.2 ± 0.9           0.109   4.2 ± 0.7           4.2 ± 0.7           4.3 ± 0.7           0.295          0.062
  Triglycerides (mmol/l)            0.8 (0.6--1.2)      0.9 (0.6--1.3)          1.0 (0.6--1.6)      0.005   0.7 (0.6--0.9)      0.8 (0.6--1.0)      0.8 (0.6--1.1)      4.0 × 10^−6^   5.4 × 10^−7^
  HDL cholesterol (mmol/l)          1.6 ± 0.4           1.5 ± 0.4               1.5 ± 0.4           0.587   1.6 ± 0.3           1.5 ± 0.3           1.6 ± 0.3           0.603          0.461
  LDL cholesterol (mmol/l)          3.0 ± 0.8           3.0 ± 0.9               3.1 ± 0.8           0.226   2.3 ± 0.6           2.2 ± 0.6           2.3 ± 0.6           0.933          0.349
  FPG (mmol/l)                      4.8 ± 0.4           4.8 ± 0.4               4.8 ± 0.4           0.724   4.8 ± 0.3           4.7 ± 0.3           4.7 ± 0.4           0.173          0.211
  Fasting plasma insulin (pmol/l)   43.8 (30.3--61.4)   40.2 (25.2--55.9)       42.3 (28.4--60.2)   0.449   47.1 (36.1--63.6)   44.2 (35.2--59.9)   44.8 (34.3--59.5)   0.172          0.162

Data are means ± SD or median (interquartile range). *P* values were calculated from linear regression adjusted for sex, age, and BMI (where appropriate) assuming an additive model. In the combined analysis, calculated *P* values were also adjusted for study cohorts (adult or adolescent).

###### 

Clinical and metabolic characteristics of Chinese adults and adolescents stratified according to genotypes of GCK rs1799884

                                    Hong Kong adults    Hong Kong adolescents   Combined *P*                                                                                                  
  --------------------------------- ------------------- ----------------------- ------------------- -------------- ------------------- ------------------- ------------------- -------------- --------------
  *n*                               332                 132                     12                                 652                 296                 36                                 
  BMI (kg/m^2^)                     22.8 ± 3.4          22.7 ± 2.9              22.1 ± 2.6          0.399          20.0 ± 3.6          19.7 ± 3.4          20.5 ± 3.9          0.559          0.388
  Systolic blood pressure (mmHg)    115.5 ± 16.5        113.8 ± 14.4            114.7 ± 22.2        0.201          117.8 ± 12.6        118.1 ± 12.0        119.1 ± 14.2        0.579          0.596
  Diastolic blood pressure (mmHg)   71.8 ± 11.7         71.0 ± 10.1             71.4 ± 13.3         0.319          72.6 ± 9.9          72.6 ± 9.0          71.4 ± 9.4          0.729          0.334
  Total cholesterol (mmol/l)        5.0 ± 0.9           5.0 ± 1.0               4.8 ± 1.2           0.567          4.2 ± 0.7           4.2 ± 0.7           4.0 ± 0.6           0.592          0.888
  Triglycerides (mmol/l)            0.8 (0.6--1.2)      0.9 (0.6--1.4)          0.9 (0.6--1.2)      0.138          0.8 (0.6--1.0)      0.8 (0.6--1.0)      0.7 (0.6--0.8)      0.894          0.796
  HDL cholesterol (mmol/l)          1.6 ± 0.4           1.5 ± 0.4               1.5 ± 0.4           0.011          1.6 ± 0.3           1.5 ± 0.3           1.6 ± 0.2           0.777          0.084
  LDL cholesterol (mmol/l)          2.9 ± 0.8           3.0 ± 0.7               2.8 ± 1.1           0.887          2.2 ± 0.6           2.3 ± 0.6           2.1 ± 0.5           0.504          0.647
  FPG (mmol/l)                      4.8 ± 0.4           4.9 ± 0.4               5.0 ± 0.4           6.4 × 10^−5^   4.7 ± 0.3           4.8 ± 0.3           4.8 ± 0.5           3.0 × 10^−5^   3.1 × 10^−7^
  Fasting plasma insulin (pmol/l)   40.3 (25.1--58.0)   43.2 (27.0--55.9)       44.9 (30.9--70.9)   0.681          45.8 (36.1--61.6)   44.2 (33.9--59.0)   45.8 (36.2--58.7)   0.978          0.878

Data are expressed as means ± SD or median (interquartile range). *P* values were calculated from linear regression adjusted for gender, age, and BMI (where appropriate) assuming an additive model. In the combined analysis, calculated *P* values were also adjusted for study cohorts (adult or adolescent).
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